Printer Friendly

Heart groups affirm utility of metabolic syndrome diagnosis.

Less than a month after two major diabetes organizations called metabolic syndrome a poorly defined and misleading diagnosis, the American Heart Association and the National Heart, Lung, and Blood Institute issued a joint statement reaffirming that the syndrome is valid and clinically useful.

The new AHA/NHLBI scientific statement basically confirms the recommendations on diagnosis and management of metabolic syndrome that were issued in 2001 as part of the National Cholesterol Education Program (NCEP) Adult Treatment Panel III (ATP III) report.

The statement also clarifies some issues, however, and provides some minor modifications to the ATP III definition of the metabolic syndrome--a term that denotes the clustering of interrelated metabolic risk factors for atherosclerotic cardiovascular disease.

Compared with the joint statement that was published last month by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD), the AHA/NHLBI statement offers a clearly different perspective on the meaning and value of a term that's now commonplace in the medical literature.

"Metabolic syndrome is a valuable clinical tool. Physicians must pay attention to it, and they must give enough attention to lifestyle [intervention]," said Scott M. Grundy, M.D., director of the Center for Human Nutrition at the University of Texas Southwestern Medical Center in Dallas.

Dr. Grundy chaired the panel that wrote the joint statement.

While the diabetes organizations questioned the value of the syndrome as a predictor of cardiovascular disease--they said, for instance, that it's "uncertain" whether it's a useful marker of cardiovascular disease risk "above and beyond the risks associated with its individual components"--the AHA/NHLBI panel maintained that it's an important and useful predictor.

The absolute short-term (10-year) risk for major coronary heart disease events is not necessarily high--and may be best assessed by Framingham risk scoring--but the longer-term risk associated with the metabolic syndrome is "undoubtedly" elevated, regardless of the Framingham score, the panel said (Circulation 2005;DOI:10.1161/circulationaha. 105.169404).

"The long-term risk is more than the sum of the parts--the risk multiplies," said Dr. Grundy.

"Nobody is asserting that metabolic syndrome is a disease. No one is saying it's a unified entity. It's a group of factors that tend to cluster together, and the diagnosis gives physicians an opportunity to identify people at long-term risk," said James I. Cleeman, M.D., cochair of the panel and coordinator of the NHLBI's National Cholesterol Education Program.

"There's no question that risk increases when these risk factors [cluster]," he said in an interview.

Overall, the syndrome increases the risk for atherosclerotic cardiovascular disease 1.5-3 times and raises the risk for type 2 diabetes 3-5 times, he and Dr. Grundy said in an interview.

The new statement essentially "ties up loose ends" and synthesizes information presented at NIH-sponsored conferences held after the ATP III report was released, Dr. Grundy said.

The statement maintains the same diagnostic criteria for metabolic syndrome--elevated waist circumference, elevated triglycerides, reduced HDL-C, elevated blood pressure, and elevated fasting glucose--and the requirement that three of the five criteria be present for a diagnosis.

It also offers the following modifications and clarifications:

* The threshold for elevated fasting glucose is reduced from 110 to 100 mg/dL, in accordance with the ADA's recently revised definition.

* Triglycerides, HDL-C levels, and blood pressure may be counted as abnormal when a patient is taking drug treatment for these factors.

* The threshold for waist circumference (102 cm in men and 88 cm in women) may be lowered in individuals or ethnic groups, particularly Asian Americans, who are prone to insulin resistance.

The panel maintained that individuals who have established atherosclerotic cardiovascular disease or type 2 diabetes can still have the metabolic syndrome--a position that is at odds with the ADA-EASD statement.

The modified ATP III definition is almost identical to the definition released--also last month--by the International Diabetes Federation, Dr. Cleeman said. One difference is that the IDF requires the presence of abdominal obesity for diagnosis.

More research is needed on the most appropriate therapies for patients with the metabolic syndrome, but for now the "prime emphasis" should be on lifestyle interventions, according to the joint statement.

Drug therapies for specific risk factors "may be indicated" when lifestyle changes are not sufficient, the statement said.

It cautions, however, against prescribing drugs that purportedly target underlying causes of the syndrome (namely obesity and insulin resistance) until evidence is sufficient.

While the AHA / NHLBI statement was in the works before the ADA and EASD released their joint statement, the effort by the diabetes organizations sent at least one other group scrambling.

The American Association of Clinical Endocrinologists last month had a "rapid-response task force" reviewing its 2003 position paper on what it calls the "insulin resistance syndrome."

"With the critical appraisal by the ADA, we want a well-thought-out, evidence-based response to clarify our position [on the issue]," said Jeffrey I. Mechanick, M.D., an endocrinologist who is leading the task force.

CHRISTINE KILGORE

Contributing Writer
COPYRIGHT 2005 International Medical News Group
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2005 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Author:Kilgore, Christine
Publication:Pediatric News
Geographic Code:1USA
Date:Oct 1, 2005
Words:822
Previous Article:Third-trimester alcohol exposure linked to school-age kids' attention problems.
Next Article:Children enrolled in JIA trial of new biologic Tx.
Topics:

Terms of use | Privacy policy | Copyright © 2019 Farlex, Inc. | Feedback | For webmasters